Your session is about to expire
← Back to Search
DCBY02 for Solid Tumors
Study Summary
This trial is testing two different types of monotherapy (single treatment) for advanced or metastatic solid tumors. Part A is testing compound DCBY02 while Part B is testing compound DCSZ11 (which is not yet active).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had a blood clot in my arteries in the last 3 months.I have severe heart disease or an uncontrolled heart condition.I am 18 years old or older.I have active cancer spread to my brain or spinal cord.I haven't had cancer in the last 3 years, except for certain treated or localized types.I am not pregnant and agree to use effective birth control.My heart's pumping ability is below normal.I have severe protein in my urine or a condition called nephrotic syndrome.I agree to have two biopsies for my cancer, which is not brain cancer (GBM), and it's safe to do so.My lab tests show my organs and bone marrow are working well.I have recovered from side effects of my previous treatment, or they are now stable.I do not have active hepatitis B or C infections.I can take care of myself and am up and about more than half of my waking hours.I am a man who will not have children and will use birth control or abstain from sex.I haven't had blood clots or lung artery issues in the last month.My cancer is incurable or has spread and may benefit from specific immune therapy.I haven't had major surgery in the last 4 weeks or minor surgery in the last 2 weeks.I haven't taken any cancer drugs or been in a trial within the last 14 days.My cancer has worsened despite treatment, and I can't tolerate or have failed all known effective therapies.
- Group 1: Part 1: Dose Escalation
- Group 2: Part 2: Dose Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research team currently recruiting participants?
"According to the records available on clinicaltrials.gov, this medical study is actively recruiting participants. It was initially published on October 26th 2022 and its details were most recently refreshed November 7th of that same year."
How many participants will be part of this research endeavor?
"Affirmative. According to info found on clinicaltrials.gov, this study is actively recruiting participants since October 26th 2022 and the last update was made in November 7th 2022. This trial requires 96 individuals from one centre for participation."
Could you elaborate on the potential risks associated with Part 1A Dose Escalation?
"There is limited safety and efficacy data in regards to Part 1A Dose Escalation, so it has been allotted a value of 1 on the risk spectrum."
Share this study with friends
Copy Link
Messenger